Astria Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Astria Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Astria Therapeutics: 6 sponsored US clinical trials, 2 recruiting.
Astria Therapeutics sponsors 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 2 completed. 1 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hereditary Angioedema, with 2 trials.
Upper-quartile sponsor footprint
Astria Therapeutics sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
A Trial to Compare the Pharmacokinetics of Two Presentations of Navenibart in Healthy Participants
NCT07635095
A Study of Navenibart in Participants With Hereditary Angioedema
NCT06842823
A Study of STAR-0310 in Healthy Adult Participants
NCT06782477
A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
NCT06007677
A Study of STAR-0215 in Participants With Hereditary Angioedema
NCT05695248
A Study of STAR-0215 in Healthy Adult Participants
NCT05477160
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the Astria Therapeutics pipeline
2 recruiting of 6 indexed (33% open); 2 completed (33%).
Phase mix: 1 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Hereditary Angioedema (2 trials), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Astria Therapeutics: open-pipeline peers nationwide
Peers matched on 6 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Astria Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
Related
What to do with this Astria Therapeutics page
6 registered trials is a research-attention snapshot, not an endorsement of Astria Therapeutics or any single study.
- 2 of Astria Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Hereditary Angioedema is the condition Astria Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hereditary Angioedema trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Astria Therapeutics pipeline card: 6 registered trials from official public datasets.Report a data error.